Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

(2023) Adrianus Johannes de Langen et al.   LANCET

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

(2022) Howard Jack West et al.   Journal for ImmunoTherapy of Cancer

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition

(2022) Bob T. Li et al.   NATURE MEDICINE

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

(2022) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

(2022) Justin Jee et al.   NATURE MEDICINE

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

(2021) Hossein Borghaei et al.   JOURNAL OF CLINICAL ONCOLOGY

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

(2021) Ferdinandos Skoulidis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to KRASG12C Inhibition in Cancer

(2021) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diverse alterations associated with resistance to KRAS(G12C) inhibition

(2021) Yulei Zhao et al.   NATURE

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

(2021) Biagio Ricciuti et al.   Journal of Thoracic Oncology

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

(2020) Jenny Y. Xue et al.   NATURE

NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes

(2020) Anju Singh et al.   CLINICAL CANCER RESEARCH

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

A mathematical model of ctDNA shedding predicts tumor detection size

(2020) Stefano Avanzini et al.   Science Advances

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

(2019) Fabrice Barlesi et al.   Journal of Thoracic Oncology

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

(2019) Edward B. Garon et al.   JOURNAL OF CLINICAL ONCOLOGY

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

(2019) Pedram Razavi et al.   NATURE MEDICINE

Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057

(2018) Martin Reck et al.   EUROPEAN JOURNAL OF CANCER

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

(2017) Pasi A. Jänne et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE